DOCSLIB.ORG

Gentamicin A2 by Heterologous Expression of Its Minimal Gene Set

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gentamicin A2 by Heterologous Expression of Its Minimal Gene Set Genetic dissection of the biosynthetic route to gentamicin A2 by heterologous expression of its minimal gene set Je Won Park†, Jay Sung Joong Hong‡, Niranjan Parajuli†, Won Seok Jung‡, Sung Ryeol Park†, Si-Kyu Lim§, Jae Kyung Sohng¶, and Yeo Joon Yoon†ʈ †Division of Nano Sciences, Ewha Womans University, 11-1 Daehyung-dong, Seodaemun-gu, Seoul 120-750, Republic of Korea; ‡Interdisciplinary Program of Biochemical Engineering and Biotechnology, Seoul National University, San 56-1, Shilim-dong, Gwanak-gu, Seoul 151-742, Republic of Korea; §Genotech Corporations, 59-5 Jang-dong, Usung-gu, Daejon 305-343, Republic of Korea; and ¶Department of Pharmaceutical Engineering, Institute of Biomolecule Reconstruction, Sun Moon University, 100 Kalsanri, Tangjeonmyun, Asansi, Chungnam 336-708, Republic of Korea Communicated by Arnold L. Demain, Drew University, Madison, NJ, April 10, 2008 (received for review November 1, 2007) Since the first use of streptomycin as an effective antibiotic drug in minor components of gentamicin are also produced by Mi- the treatment of tuberculosis, aminoglycoside antibiotics have cromonospora echinospora, including gentamicin A2 (4a), the been widely used against a variety of bacterial infections for over precursor from which other forms of gentamicin are derived (4). six decades. However, the pathways for aminoglycoside biosyn- The recent discovery of gene clusters for biosynthesis of thesis still remain unclear, mainly because of difficulty in genetic butirosin and neomycin in Bacillus circulans and Streptomyces manipulation of actinomycetes producing this class of antibiotics. fradiae, respectively, has facilitated genetic and biochemical Gentamicin belongs to the group of 4,6-disubstituted aminogly- studies on the biosynthesis of 4,5-disubstituted aminoglycosides cosides containing a characteristic core aminocyclitol moiety, 2- (5–9). Concurrently, the biosynthetic gene clusters relating to the deoxystreptamine (2-DOS), and the recent discovery of its biosyn- 4,6-disubstituted aminoglycosides kanamycin, tobramycin, and thetic gene cluster in Micromonospora echinospora has enabled us gentamicin have been isolated from Streptomyces kanamyceticus, to decipher its biosynthetic pathway. To determine the minimal set Streptomyces tenebrarius, and M. echinospora, respectively (10– of genes and their functions for the generation of gentamicin A2, 13). However, little progress has been made to evaluate the the first pseudotrisaccharide intermediate in the biosynthetic path- proposed biosynthetic routes to these antibiotics, mainly because way for the gentamicin complex, various sets of candidate genes of difficulty in genetic manipulation of the producing microor- from M. echinospora and other related aminoglycoside-producing ganisms. Gentamicin-producing M. echinospora has innate re- strains were introduced into a nonaminoglycoside producing strain sistance to most antibiotics precluding the use of standard of Streptomyces venezuelae. Heterologous expression of different Streptomyces cloning vectors displays low transformation effi- combinations of putative 2-DOS biosynthetic genes revealed that ciency (Ͻ10Ϫ7 transformants per microgram of DNA) (14). a subset, gtmB-gtmA-gacH, is responsible for the biosynthesis of Current knowledge regarding the biosynthesis of 2-DOS con- this core aminocyclitol moiety of gentamicin. Expression of gtmG taining aminoglycosides was recently reviewed, and most of cited .(together with gtmB-gtmA-gacH led to production of 2؅-N- works relied on in vitro studies of individual gene products (15 acetylparomamine, demonstrating that GtmG acts as a glycosyl- When the biosynthetic route to the gentamicin complex was first transferase that adds N-acetyl-D-glucosamine (GLcNA) to 2-DOS. predicted, it was based on isolation of metabolites from cell -Expression of gtmM ina2؅-N-acetylparomamine-producing recom- culture extracts and precursor feeding studies of blocked mu binant S. venezuelae strain generated paromamine. Expression of tants (16, 17). However, functional studies of gentamicin bio- gtmE in an engineered paromamine-producing strain of S. ven- synthetic genes have not been possible, so that assignment of the ezuelae successfully generated gentamicin A2, indicating that roles of gene products has hitherto been based purely on amino GtmE is another glycosyltransferase that attaches D-xylose to acid sequence comparisons pending verification by direct exper- paromamine. These results represent in vivo evidence elucidating imental evidence. the complete biosynthetic pathway of the pseudotrisaccharide We show here that heterologous expression of different aminoglycoside. combinations of genes from the gentamicin biosynthetic gene cluster (refs. 11 and 12: GenBank accession nos. AJ575934 and aminoglycoside biosynthesis ͉ Micromonospora echinospora ͉ AY524043) in a nonaminoglycoside producing strain of S. ven- Streptomyces venezuelae ͉ pathway engineering ezuelae caused production of intermediates from the gentamicin biosynthetic pathway including 2-DOS (1a), 2Ј-N-acetylparo- entamicin is an aminoglycoside antibiotic complex pro- mamine (2a), paromamine (3a), and the first pseudotrisaccha- Gduced by various Micromonospora species (1). Aminogly- ride, gentamicin A2 (4a). This provided experimental evidence cosides act by binding to the bacterial ribosome inhibiting for assigning the functions of individual gene products, allowing protein synthesis and generating errors in the translation of the us to recognize a complete biosynthetic pathway for generation genetic code (2). This class of antibiotics has been used clinically for the treatment of severe bacterial infections for Ͼ60 years, beginning with the use of streptomycin to treat tuberculosis (3). Author contributions: J.W.P. and J.S.J.H. contributed equally to this work; J.W.P., N.P., S.-K.L., J.K.S., and Y.J.Y. designed research; J.W.P., J.S.J.H., N.P., W.S.J., and S.R.P. performed MICROBIOLOGY However, the genetics underlying the biosynthesis of aminogly- research; J.W.P. and J.K.S. contributed new reagents/analytic tools; J.W.P., J.S.J.H., N.P., cosides, including gentamicin, still remains unclear. Structurally, S.-K.L., J.K.S., and Y.J.Y. analyzed data; and J.W.P., J.S.J.H., and Y.J.Y. wrote the paper. gentamicin is a 4,6-disubstituted aminocyclitol composed of the The authors declare no conflict of interest. core aminocyclitol moiety, 2-deoxystreptamine (2-DOS, 1a), Data deposition: The sequences reported in this paper have been deposited in the GenBank which is decorated by purpurosamine and garosamine amin- database (accession nos. AM946392). osugars at positions C-4 and C-6, respectively. In its therapeutic ʈTo whom correspondence should be addressed. E-mail: [email protected]. form, gentamicin comprises a complex of gentamicin C1,C1a, This article contains supporting information online at www.pnas.org/cgi/content/full/ and C2, which differ only in the degree of methylation of the C-6Ј 0803164105/DCSupplemental. position of the sugar attached at C-4 of 2-DOS (Fig. 1). Other © 2008 by The National Academy of Sciences of the USA www.pnas.org͞cgi͞doi͞10.1073͞pnas.0803164105 PNAS ͉ June 17, 2008 ͉ vol. 105 ͉ no. 24 ͉ 8399–8404 Downloaded by guest on September 26, 2021 2- OPO3 6 O NH2 NH2 HO O HO HO HO 1 HO HO HO HO GtmA OH GtmB OH GacH OH OH OH OH OH O GtmB Glc- P-6 2-DOI 2-DOIA keto-2-DOIA NH2 4 2 HO 3 '6 OH 1 OH 6' OH '4 '6 HO 6 NH2 4' '4 5' O 5 5' HO OH HO '5 O HO O 2' 2' 2' HO '1 1' HO '1 NH 1a HO NH '3 HN 4 2 2 GtmG NH2 '3 2 3 3' H2N 4 2 H2N 4 2 O O 3 O 3 '7 1 1 1 HO 6 NH2 HO GtmE HO NH GtmM 5 6 NH2 6 2 O OH 5 O 5 OH '8 O "1 2a OH 3a "5 "2 "4 "3 OH HOHO "4 '2 '4 "5 O '3 H3C "2 H2N 4a "1 5' 6' H3CHN '1 O "3 OH R OH 6 4 R 2 O 5 O 1 H N 3 NH 2 1 2 2 R R 1 R 2 Gentamicin C1: CH3 NHCH3 Gentamicin C1a:H H N 2 Gentamicin C2: CH3 NH2 Fig. 1. Proposed biosynthetic pathway of gentamicin A2 (4a) and its biosynthetic intermediates 2-deoxystreptamine (1a), 2Ј-N-acetylparomamine (2a), and paromamine (3a). of gentamicin A2. This work has established an efficient in 2-DOS biosynthesis, based on its sequence homology to the heterologous expression platform based on a genetically ame- 2-DOIA dehydrogenase Neo5 [CAH58688, otherwise known as nable streptomycete to dissect the biosynthetic pathways of NeoA (BAD95818)] involved in neomycin biosynthesis. When other aminoglycoside antibiotics produced by less tractable the resultant plasmid pYJ495 harboring gtmD-gtmB-gtmA-gacH actinomycetes. was expressed in the heterologous host, 2-DOS (1a) was indeed produced (Fig. 2A). The two transamination reactions required Results and Discussion for biosynthesis of 2-DOS during butirosin production by B. Putative gentamicin biosynthetic genes, suggested by previous circulans are catalyzed by a single enzyme, BtrS [BAE07061, studies to encode the 2-DOS biosynthetic enzymes, two glyco- otherwise known as BtrR (CAD41947)] (23). To ascertain syltransferases and a deacetylase, were amplified by PCR (8, 10, whether the biosynthesis of 2-DOS during gentamicin produc- 18) and cloned into a thiostrepton-resistance vector, pSE34, tion likewise involves dual activity of a single aminotransferase, under control of the ermE* promoter (19). Plasmids harboring two separate constructs pYJ496 and pYJ497 expressing gtmB- different sets of genes necessary for the biosynthesis of genta- gtmA-gacH and gtmD-gtmA-gacH, respectively, were tested. The micin and its intermediates were heterologously expressed in a expression of gtmB, gtmA, and gacH produced Ϸ120 ␮g per liter mutant strain of S. venezuelae YJ003 that lacks the ability to of 2-DOS (1a) (corrected for Ϸ40% mean recoveries of 1a), biosynthesize its native deoxysugar (TDP-D-desosamine) (20). whereas, gtmD, gtmA, and gacH did not do so (Fig. 2 B and C), The culture extracts from the resulting strains were analyzed by indicating that GtmB catalyzes both transamination steps in the using HPLC-ESI-MS/MS to detect gentamicin-related com- synthesis of 2-DOS, whereas GtmD may act in a later step during pounds, the structures of which were then further identified by gentamicin production.
Load more

Recommended publications
  • The Use of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities
    University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Graduate School Professional Papers 2010 The seU of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities Joshua Bryant Phillips The University of Montana Let us know how access to this document benefits ouy . Follow this and additional works at: https://scholarworks.umt.edu/etd Recommended Citation Phillips, Joshua Bryant, "The sU e of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities" (2010). Graduate Student Theses, Dissertations, & Professional Papers. 1100. https://scholarworks.umt.edu/etd/1100 This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. THE USE OF NATURAL PRODUCT SUBSTRATES FOR THE SYNTHESIS OF LIBRARIES OF BIOLOGICALLY ACTIVE, NEW CHEMICAL ENTITIES by Joshua Bryant Phillips B.S. Chemistry, Northern Arizona University, 2002 B.S. Microbiology (health pre-professional), Northern Arizona University, 2002 Presented in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chemistry The University of Montana June 2010 Phillips, Joshua Bryant Ph.D., June 2010 Chemistry THE USE OF NATURAL PRODUCT SUBSTRATES FOR THE SYNTHESIS OF LIBRARIES OF BIOLOGICALLY ACTIVE, NEW CHEMICAL ENTITIES Advisor: Dr. Nigel D. Priestley Chairperson: Dr. Bruce Bowler ABSTRACT Since Alexander Fleming first noted the killing of a bacterial culture by a mold, antibiotics have revolutionized medicine, being able to treat, and often cure life-threatening illnesses and making surgical procedures possible by eliminating the possibility of opportunistic infection.
    [Show full text]
  • Apramycin Sulfate Salt (A2024)
    APRAMYCIN SULFATE ProductInformation Sigma Prod. No. A-2024 NH2 CAS NUMBER: 65710-07-8 X H2SO4 OH S PHYSICAL PROPERTIES: HO S S Absolute stereochemistry: Rotation (+) O R Appearance: Faint yellow powder R OH H H Molecular formula: C21H41N5O11 • x H2SO4 H N 2 NH2 H2N O O Molecular weight: 539.58 (free base) R S R S R S R S R S R HO R H O O N H H CH3 OH OH DESCRIPTION: Apramycin is an aminoglycoside antibiotic produced by a strain of Streptomyces tenebrarius. The compound is used as the sulfate in veterinary practice.1,2 STABILITY / STORAGE AS SUPPLIED: Store desiccated at 2-8EC. SOLUBILITY / SOLUTION STABILITY: Aqueous solutions at 25 mg/mL are faint yellow. No solution stability data are currently available. APPLICATIONS: 1. An oral composition of 20 g apramycin sulfate, 1 g pyridoxal HCl, 10 g sodium alginate, 10 g glycine and about 30 powdered apples were fed to calves and swine in order to treat diarrhea. Pyridoxal HCl was added to enhance the bactericidal activity of apramycin sulfate.3 2. Under the Federal Food, Drug and Cosmetics Act, feed containing 150 g apramycin per ton may be used to control colibacillosis.4 3. Apramycin is a potent inhibitor of protein synthesis in bacteria in vivo and in vitro. To a limited extent, it induces translation errors in cell-free systems from Escherichia coli supplemented with poly(U). Apramycin also inhibits the translocation step of protein synthesis in vivo (e.g., in protoplasts of Bacillus megaterium), and in vitro (e.g., in cell-free systems from E.
    [Show full text]
  • Functional Analysis of Spectinomycin Biosynthetic Genes from Streptomyces Spectabilis ATCC 27741
    J. Microbiol. Biotechnol. (2003), 13(6), 906–911 Functional Analysis of Spectinomycin Biosynthetic Genes from Streptomyces spectabilis ATCC 27741 JO, YOU-YOUNG1, SUN-HEE KIM1, YOUNG-YELL YANG1, CHOONG-MIN KANG2, 3 1 JAE-KYUNG SOHNG , AND JOO-WON SUH 1Department of Biological Science, Institute of Bioscience and Biotechnology, Myong Ji University, Yongin 449-728, Korea 2Childrens Hospital, Harvard Medical School, Boston, MA 02467, U.S.A. 3Department of Chemistry, SunMoon University, Asansi, Chungnam 337-840, Korea Received: May 23, 2003 Accepted: July 15, 2003 Abstract The function of genes related to spectinomycin Spectinomycin is an aminoglycoside antibiotic produced biosynthesis (spcD, speA, speB, spcS2) from Streptomyces by several Streptomyces species such as Streptomyces spectabilis ATCC 27741, a spectinomycin producer, was analyzed. flavopersicus [17], Streptomyces hygroscopicus [31], and Each gene was subcloned from a spectinomycin biosynthetic Streptomyces spectabilis [15]. The antibiotic has a unique gene cluster and overexpressed in E. coli BL21 (DE3) using tricyclic structure in which a single sugar component, pET vector. After incubating each purified protein with its actinospectose, is linked to the diaminocyclitol moiety possible substrates, the final products were analyzed using (actinamine) by β-glycosidic and hemiketal bonds [4, 30]. high-performance liquid chromatography (HPLC). From these It blocks the translocation step of protein synthesis by results, spcD, speA, and speB have been identified to be inhibiting the binding of the elongation factor G to the dTDP-glucose synthase, myo-inositol monophosphatase, and ribosome [3]. It possesses a broad spectrum of activities myo-inositol dehydrogenase, respectively. In addition, the against many Gram-positive as well as Gram-negative results suggest that the spcS2 gene product functions downstream bacteria [29].
    [Show full text]
  • Introduction (Pdf)
    Dictionary of Natural Products on CD-ROM This introduction screen gives access to (a) a general introduction to the scope and content of DNP on CD-ROM, followed by (b) an extensive review of the different types of natural product and the way in which they are organised and categorised in DNP. You may access the section of your choice by clicking on the appropriate line below, or you may scroll through the text forwards or backwards from any point. Introduction to the DNP database page 3 Data presentation and organisation 3 Derivatives and variants 3 Chemical names and synonyms 4 CAS Registry Numbers 6 Diagrams 7 Stereochemical conventions 7 Molecular formula and molecular weight 8 Source 9 Importance/use 9 Type of Compound 9 Physical Data 9 Hazard and toxicity information 10 Bibliographic References 11 Journal abbreviations 12 Entry under review 12 Description of Natural Product Structures 13 Aliphatic natural products 15 Semiochemicals 15 Lipids 22 Polyketides 29 Carbohydrates 35 Oxygen heterocycles 44 Simple aromatic natural products 45 Benzofuranoids 48 Benzopyranoids 49 1 Flavonoids page 51 Tannins 60 Lignans 64 Polycyclic aromatic natural products 68 Terpenoids 72 Monoterpenoids 73 Sesquiterpenoids 77 Diterpenoids 101 Sesterterpenoids 118 Triterpenoids 121 Tetraterpenoids 131 Miscellaneous terpenoids 133 Meroterpenoids 133 Steroids 135 The sterols 140 Aminoacids and peptides 148 Aminoacids 148 Peptides 150 β-Lactams 151 Glycopeptides 153 Alkaloids 154 Alkaloids derived from ornithine 154 Alkaloids derived from lysine 156 Alkaloids
    [Show full text]
  • Amikacin: Uses, Resistance, and Prospects for Inhibition
    molecules Review Amikacin: Uses, Resistance, and Prospects for Inhibition Maria S. Ramirez and Marcelo E. Tolmasky * Center for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, CA 92831, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-657-278-5263 Received: 27 November 2017; Accepted: 14 December 2017; Published: 19 December 2017 Abstract: Aminoglycosides are a group of antibiotics used since the 1940s to primarily treat a broad spectrum of bacterial infections. The primary resistance mechanism against these antibiotics is enzymatic modification by aminoglycoside-modifying enzymes that are divided into acetyl-transferases, phosphotransferases, and nucleotidyltransferases. To overcome this problem, new semisynthetic aminoglycosides were developed in the 70s. The most widely used semisynthetic aminoglycoside is amikacin, which is refractory to most aminoglycoside modifying enzymes. Amikacin was synthesized by acylation with the L-(−)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A. The main amikacin resistance mechanism found in the clinics is acetylation by the aminoglycoside 60-N-acetyltransferase type Ib [AAC(60)-Ib], an enzyme coded for by a gene found in integrons, transposons, plasmids, and chromosomes of Gram-negative bacteria. Numerous efforts are focused on finding strategies to neutralize the action of AAC(60)-Ib and extend the useful life of amikacin. Small molecules as well as complexes ionophore-Zn+2 or Cu+2 were found to inhibit the acetylation reaction and induced phenotypic conversion to susceptibility in bacteria harboring the aac(60)-Ib gene. A new semisynthetic aminoglycoside, plazomicin, is in advance stage of development and will contribute to renewed interest in this kind of antibiotics.
    [Show full text]
  • Biochemical Basis of Resistance to Hygromycin B in Streptomyces Hygroscopicus - the Producing Organism
    Journal of General Microbiology (1985), 131, 1289-1 298. Printed in Great Britain 1289 Biochemical Basis of Resistance to Hygromycin B in Streptomyces hygroscopicus - the Producing Organism By JOSE MANUEL PARDO,' FRANCISCO MALPARTIDA,' MANUEL RICO~AND ANTONIO JIMENEZ~* Centro de Biologia Molecular, CSIC and UAM, Universidad Autbnoma de Madrid, Canto Blanco, Madrid 28049, Spain Instituto Rocasolano de Quimica Fisica, Serrano 117, Madrid 28006, Spain (Received I0 December I984 ;revised 31 January 1985) Hygromycin B, an aminocyclitol antibiotic that strongly inhibits both 70s and 80s ribosomes, is synthesized by Streptomyces hygroscopicus. Ribosomes from this Gram-positive mycelial bacterium are inhibited in vitro by the antibiotic. In contrast, the streptomycete is highly resistant to the drug in vivo since it possesses hygromycin B phosphotransferase activity. This enzyme has been shown by gel filtration to have a molecular weight of 42000, and to modify its antibiotic substrate to produce 7"-O-phosphoryl-hygromycinB which totally lacks biological activity both in vivo and in vitro. INTRODUCTION The aminocyclitol antibiotic hygromycin B (Fig. 1) is produced by Streptomyces hygroscopicus and specifically blocks the translocation step on both 70s and 80s ribosomes (Cabaiias et al., 1978; Gonzilez et al., 1978). The drug also induces misreading both in vivo and in vitro and therefore promotes phenotypic suppression (Cabaiias et al., 1978; Singh et al., 1979). S. hygroscopicus contains a phosphotransferase (HPH) activity which phosphorylates hygromycin B, thus potentially providing the producing organism with autoimmunity against the toxic 7" CHzOH HO 16'' HO 6' NHCH, CHNH? 4" b NH, 0 HO Destomic Acid D-TalOSe H yosamine Fig.
    [Show full text]
  • Apramycin and Gentamicin Resistance in Escherichia Coli and Salmonellas Isolated from Farm Animals by C
    J. Hyg., Camb. (1986), 97, 445-456 445 Printed in Great Britain Apramycin and gentamicin resistance in Escherichia coli and salmonellas isolated from farm animals BY C. WRAY*, R. W. HEDGESt, K. P. SHANNON: AND D. E. BRADLEY§ * Ministry of Agriculture, Fisheries and Food, Central Veterinary Laboratory, New Haw, Weybridge, Surrey, KT15 3NB, UK, t Plant Genetic Systems, J. Plateau Straat 22, B-9000 Ghent, Belgium, t Department of Microbiology, United Medical and Dental Schools of Guy's and St Thomas's Hospitals, St Thomas's Campus, London SE1 7EH, UK and § Faculty of Medicine, Memorial University of Newfoundland, St John's, Newfoundland, Canada AlB 3 V6 (Received and accepted in revised form 22 July 1986) SUMMARY Since the aminoglycoside antibiotic apramycin was licensed for veterinary use in 1980, all isolates of Escherichia coli and salmonellas received at the Central Veterinary Laboratory have been monitored for resistance to apramycin and the related antibiotic gentamicin. During the period 1982-4, the incidence ofresistance in E. coli to apramycin increased from 0-6 % in 1982 to 2-6 % in 1984. In salmonellas the incidence of resistance to apramycin increased from 0'1 % in 1982 to 1-4 % in 1984. Resistance to both apramycin and gentamicin was detected in six different salmonella serotypes, although an isolate ofSalmonella thompson from poultry was resistant to gentamicin but not apramycin. Most of the cultures were isolated from pigs, although the incidence of apramycin resistance in S. typhimurium (DT 204C) from calves has shown a recent dramatic increase. All the isolates with one exception produced the enzyme aminoglycoside 3-N-acetyltransferase IV (ACC(3)IV).
    [Show full text]
  • Streptomycin.Pdf
    DaMocles SS 2015 Gruppe D Lukas Koser, Yannick Kristiansen, Annika Lill, Tim Maier Dozent: Prof. Dr. Wolf Dieter Fessner Streptomycin 1. Streptomycin, an Aminoglycoside Streptomycin (5-(2,4-Diguanidino- 3,5,6-trihydroxy- cyclohexoxy)- 4-[4,5-dihydroxy- 6-(hydroxymethyl)- 3- methylamino- tetrahydropyran-2-yl]oxy- 3-hydroxy-2-methyl- tetrahydrofuran- 3-carbaldehyd; C21H39N7O13 ) is an antibiotic drug of the drug class called aminoglycosides. It is produced by different Streptomyces, which are found in soil. It is used in human medicine and sometimes it is used in agriculture against fire blight (a contagious disease triggered by Erwinia amylovora (Enterobacteriaceae)1. General Information: 2 Molecular mass:581,6 g/mol CAS Registry Number:57-92-1 GHS label: H302: Harmful if swallowed Toxicological data: LD50 (Rat, oral) 9000mg/kg 2. History On 19th October 1943 Streptomycin was first discovered by Albert Schatz , Elizabeth Bugic and Selman Maksman. Streptomycin was very useful against causative organism of tuberculosis.3 While various causative organisms could be fought with penicilin (first isolation by Alexander 1 https://de.wikipedia.org/wiki/Feuerbrand 2 https://de.wikipedia.org/wiki/Streptomycin 3 https://de.wikipedia.org/wiki/Streptomycin Fleming in 1928), there was no useful medicine against tubercolosis. This fact makes the discover of Streptomycin to a historical event. Selman Waksman was awarded with a Nobel Price for medicine in 19524. Bugie and Schatz were excluded. 3. Biosynthesis Streptomycin is produced by the bacteria Streptomyces griseus. Streptomycin consists of aminocyclitol (streptidine), 6-deoxyhexose (streptose), and N-methyl-L-glucosamine moieties, which are formed by independent biosynthetic pathways. All of them are derivated from D-Glucose.
    [Show full text]
  • MRL-Spectinomycin (Cattle,Pigs and Poultry)
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/726/00-FINAL March 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS SPECTINOMYCIN (cattle, pigs and poultry) SUMMARY REPORT (3) 1. Spectinomycin is an aminocyclitol antibiotic produced by Streptomyces spectabilis.Itexertsits bacteriostatic effect by binding to the 30S subunit of bacterial ribosomes and inhibiting the translation of protein synthesis. Spectinomycin is indicated for use via the oral and parenteral routes, often in conjunction with lincomycin, in the treatment of a variety of enteric, respiratory and other infections of cattle, sheep, pigs and poultry. In veterinary medicine spectinomycin is used as hydrocloride and sulphate salts. In cattle including lactating cows, products are given by intramuscular injection at a dosage of 30 mg/kg bw/day or subcutaneous injection at 15 mg/kg bw/day, in both cases for 5 consecutive days. In pigs, spectinomycin is administered in the diet at 22 mg/kg feed for 21 consecutive days or as an intramuscular injection of 11 mg/kg bw. In chickens, spectinomycin is administered orally in drinking water and feed at doses equivalent to 100 mg/kg bw/day for 3 to 7 days. Spectinomycin is currently entered into Annex III of Council Regulation (EEC) No 2377/90 in accordance with the following tables: Pharmacologically Marker residue Animal MRLs Target Other provisions active substance(s) species tissues Spectinomycin Spectinomycin Bovine, 300 µg/kg Muscle Provisional MRLs porcine, 500 µg/kg Fat expire on poultry 2000 µg/kg Liver 01.07.2000 5000 µg/kg Kidney Bovine 200 µg/kg Milk Pharmacologically Marker residue Animal MRLs Target Other provisions active substance(s) Species tissues Spectinomycin Spectinomycin Ovine 300 µg/kg Muscle Provisional MRLs 500 µg/kg Fat expire on 2000 µg/kg Liver 01.01.2002.
    [Show full text]
  • Aminoglycosides*
    Aminoglycosides* Overview Included in this group of bactericidal agents are streptomycin, dihydrostreptomycin, neomycin, framycetin (neomycin B), paromomycin (aminosidine), kanamycin, gentamicin, tobramycin, amikacin, sisomicin and netilmicin. Streptomycin, the first aminoglycoside, was introduced in 1942 for treatment of tuberculosis. Aminoglycosides are characterized by an aminocyclitol ring with aminosugars attached in a glycoside linkage. Because of minor differences in molecular substitutions, aminoglycoside antibiotics may actually consist of several forms of a single aminoglycoside. For example, gentamicin is made up of gentamicins C1 and C2, and neomycin is composed of neomycin B, C and fradiomycin. Removal of hydroxyl groups on the aminosugar components markedly increases antibiotic activity. Although not structurally identical, spectinomycin and apramycin are also considered to be aminoglycosides. Aminoglycosides are usually quite stable chemicals and are very poorly absorbed (<10%) from a healthy gastrointestinal tract. Inflammation and other pathology in the gut may significantly increase absorption. Subcutaneous administration may also result in protracted absorption. Intramuscular, intraperitoneal and intravenous administration usually results in rapid and almost complete absorption of the drug, but intraperitoneal and intravenous injections are characterized by a high risk of toxicity. The site of action of aminoglycosides is the membrane associated bacterial ribosome, specifically the 30S subunit where irreversible binding
    [Show full text]
  • SPECTINOMYCIN (Veterinary—Systemic)
    SPECTINOMYCIN (Veterinary—Systemic) Some commonly used brand names for veterinary-labeled products and H. somnus in cattle.{R-21; 22} are: Adspec Sterile Solution; Spectam; Spectam Injectable; ELCANSalmonella infantis infection (treatment)EL—Chicks, newly Spectam Oral Solution; Spectam Scour-Halt; Spectam Powder; hatched: Spectinomycin hydrochloride injection is indicated in Spectam Water Soluble; Spectam Water Soluble Concentrate; and the control of mortality and to lessen severity of infections caused Spectoguard Scour-Chek. by S. infantis;{R-17} however, S. infantis is not considered to be a major pathogen in the poultry industry. Note: For a listing of dosage forms and brand names by country Synovitis (prophylaxis)—Chickens, broiler: Spectinomycin powder availability, see the Dosage Forms section(s). for oral solution is indicated to aid in the prevention of mortality associated with infectious synovitis due to susceptible {R-2; 18} Category: Antimicrobial (systemic). Mycoplasma synoviae. Synovitis (treatment)— ELCANChickens, broilerEL: Spectinomycin powder for oral solution Indications: is indicated to aid in the control of mortality associated with ELUS EL Note: The text between and describes uses that are not included infectious synovitis due to susceptible M. synoviae.{R-18} ELCAN EL in U.S. product labeling. Text between and describes uses ELCANChicks, newly hatchedEL: Spectinomycin hydrochloride that are not included in Canadian product labeling. injection is indicated in the control of mortality and to lessen The ELUS or ELCAN designation can signify a lack of product severity of infections caused by susceptible M. synoviae.{R-17} availability in the country indicated. See the Dosage Forms ELUSFowl cholera (treatment)EL—Turkeys: Spectinomycin section of this monograph to confirm availability.
    [Show full text]
  • Biosynthetic Genes for Aminoglycoside Antibiotics
    The Journal of Antibiotics (2009) 62, 471–481 & 2009 Japan Antibiotics Research Association All rights reserved 0021-8820/09 $32.00 www.nature.com/ja REVIEW ARTICLE Biosynthetic genes for aminoglycoside antibiotics Fumitaka Kudo1 and Tadashi Eguchi2 Biosynthetic studies of aminoglycoside antibiotics have progressed remarkably during the last decade. Many biosynthetic gene clusters for aminoglycoside antibiotics including streptomycin, kanamycin, butirosin, neomycin and gentamicin have been identified to date. In addition, most butirosin and neomycin biosynthetic enzymes have been functionally characterized using recombinant proteins. Herein, we reanalyze biosynthetic genes for structurally related 2-deoxystreptamine (2DOS)-containing aminoglycosides, such as kanamycin, gentamicin and istamycin, based on genetic information including characterized biosynthetic enzymes in neomycin and butirosin biosynthetic pathways. These proposed enzymatic functions for uncharacterized enzymes are expected to support investigation of the complex biosynthetic pathways for this important class of antibiotics. The Journal of Antibiotics (2009) 62, 471–481; doi:10.1038/ja.2009.76; published online 31 July 2009 Keywords: aminoglycoside antibiotics; aminocyclitol; biosynthesis; biosynthetic enzyme; biosynthetic gene INTRODUCTION Biosynthetic studies of aminoglycosides have indeed been per- Aminoglycoside antibiotics are known as a classical but clinically formed for many years. Initially, feeding experiments with radio- important class of agents, especially
    [Show full text]